

AMENDMENTS TO THE CLAIMS

Please cancel claim 16 without prejudice or disclaimer to its underlying subject matter.
Please amend claims 10-11, 14-15 and 17 as set forth below:

*Dono X
mh 8/19/03*

8. (Previously presented) A deoxyribonucleic acid (DNA) vaccine comprising a liposome-encapsulated plasmid containing a gene encoding for hemagglutinin protein.

9. (new) The vaccine as claimed in Claim 8 deliverable to a respiratory tract using intranasal administration and/or by aerosol inhalation.

10. (currently amended) The deoxyribonucleic acid (DNA) vaccine of claim 8, Use of the vaccine of claim 8 for preventing and/or treating wherein the vaccine prevents or treats an influenza virus infection.

11. (currently amended) The deoxyribonucleic acid (DNA) vaccine of claim 8, Use of the vaccine of claim 8 for eliciting wherein the vaccine elicits long-lasting protective antiviral immune responses against influenza viruses.

12. (Previously presented) A plasmid vector construct pCI-HA10 comprising a gene encoding for hemagglutinin protein and capable of expressing said hemagglutinin protein in a host.

13. (Previously presented) A method for constructing a plasmid pCI-HA10 comprising the following steps:

- (1) amplifying hemagglutinin gene from viral and mRNA with PCR;
- (2) inserting and ligating the hemagglutinin gene into a pCI vector;
- (3) transforming the resulting vector into competent E.coli DH5 α cells;
- (4) transcribing and translating of pCI-HA10; and
- (5) preparing and purifying pCI-HA10 by bulk preparation method.

14. (currently amended) A liposome formulation for encapsulating the The method of constructing the plasmid pCI-HA10 of claim 1213, further comprising the step of encapsulating the plasmid pCI-HA10 in a liposome formulation, said liposome formulation comprising of 7% 1,2 dioleoyl-3-dimethylammonium chloride (DODAC), 78% 1,2-dioleoyl-sn-glycerol-3-phospho-ethanolamine (DOPE) and 15% polyethylene glycol C8 ceramide (PEG₂₀₀₀C₈CER).

15. (currently amended) A method for encapsulating The method of constructing the plasmid pCI-HA10 of claim 1213, further comprising the step of encapsulating the plasmid pCI-HA10 in a liposome formulation, into liposomes comprising the following steps:

- (1) preparing 7% DODAC, 78% DOPE, and 15% PEG₂₀₀₀C₈CER at 10mg/ml concentrations to form a lipid film at 50 °C for 2h under vacuum;
- (2) incubating the lipid film at 50 °C for 2h under vacuum;
- (3) reconstituting the lipid film with distilled water and 1M β-octylglucanopyranoside detergent at 20% of the total preparation volume;
- (4) adding the plasmid DNA to the lipid film at a concentration of 400 µg DNA/ml of 10 mg/ml;
- (5) transferring the reconstituted preparation into dialysis tubing and dialyzing in 1X HEPES buffer solution (150 mM NaCl, 20 mM Hepes, pH 7.4) at 23 °C for 15 h; and
- (6) removing the free, non-encapsulate DNA from encapsulated DNA on a DEAE Sepharose CL-6B anion exchange column.

16. (cancelled)

17. (currently amended) The method of constructing A method of delivering the liposome-encapsulated the plasmid pCI-HA10 of claim 16-15, further comprising the step of delivering the liposome-encapsulated pCI-HA10 to a respiratory tract using intranasal administration, and/or aerosol inhalation to eliciting protective antiviral immune responses to influenza viruses.

18. (Previously presented) A method for preventing and/or treating influenza virus infection, comprising administering to a patient in need thereof a pharmaceutically effective amount of the vaccine of claim 8.

19. (Previously presented) A method for eliciting long-lasting protective antiviral immune responses against influenza viruses, comprising administering to a patient in need thereof a pharmaceutically effective amount of the vaccine of claim 8.